Macugen maintenance

Article

Macugen maintenance

OSI Pharmaceuticals and Pfizer have announced the initiation of a Phase IV trial to explore the safety and efficacy of Macugen (pegaptanib sodium injection) as a maintenance therapy for patients who have received prior wet age related macular degeneration (AMD) treatment and experienced improvement in their condition.

LEVEL (evaLuation of Efficacy and safety in maintaining Visual acuity with sEquential treatment of neovascuLar AMD), is an open label, multicentre trial, open to subjects who have had at least one, but no more than three, treatments for wet AMD within 30 to 120 days prior to the study. The 54-week trial comprises of up to 1,000 patients at 100 sites across the USA. Macugen will be administered once every six weeks for 48 weeks, booster treatment may be employed if the investigator believes macular disease has progressed.

The primary endpoint is the percentage of patients who remain at baseline vision or gain (more than or equal to 0 lines) vision from baseline to 54 weeks. Secondary endpoints include the percentage of patients maintaining or gaining one, two and three lines of visual acuity at week 54 compared with pre-enrolment baseline vision; mean change of visual acuity from baseline to week 54; percentage of subjects losing less than three lines of vision at week 54; and anatomical outcomes on fluorescein angiography and optical coherence tomography.

Macugen is already an approved treatment for wet AMD in North America, Europe, Brazil, Argentina, Peru, Pakistan and The Philippines. This study hopes to demonstrate that the drug can continue to be effective over an extended period of time.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.